Any feedback?
Please rate this page
(all_enzymes.php)
(0/150)

BRENDA support

2.4.1.129: peptidoglycan glycosyltransferase

This is an abbreviated version!
For detailed information about peptidoglycan glycosyltransferase, go to the full flat file.

Word Map on EC 2.4.1.129

Reaction

[GlcNAc-(1->4)-Mur2Ac(oyl-L-Ala-gamma-D-Glu-L-Lys-D-Ala-D-Ala)]n-diphosphoundecaprenol
+
GlcNAc-(1->4)-Mur2Ac(oyl-L-Ala-gamma-D-Glu-L-Lys-D-Ala-D-Ala)-diphosphoundecaprenol
=
[GlcNAc-(1->4)-Mur2Ac(oyl-L-Ala-gamma-D-Glu-L-Lys-D-Ala-D-Ala)]n+1-diphosphoundecaprenol
 +
undecaprenyl diphosphate

Synonyms

bacterial cell wall glycosyltransferase, bactoprenyldiphospho-N-acetylmuramoyl-(N-acetyl-D-glucosaminyl)-pentapeptide:peptidoglycan N-acetylmuramoyl-N-acetyl-D-glucosaminyltransferase, bifunctional penicillin-binding protein, class A penicillin-binding protein, class B penicillin-binding protein, DD-transpeptidase, ftsI, glycosyltransferase, peptidoglycan, glycosyltransferase/acyltransferase penicillin-binding protein 4, GTase, MGT, monofunctional glycosyltransferase, mrcB, MtgA, murein synthase, PBP, PBP 1a, PBP 2b, PBP 2x, PBP 3, PBP-1A, PBP-1B, PBP-1C, PBP-2, PBP1, PBP1a, PBP1b, PBP1c, PBP2, PBP2A, PBP2b, PBP2c, PBP2d, PBP3, PBP4, PBP7, PBP8, PBPA, PenA, penicillin binding protein, penicillin binding protein 1b, penicillin-binding protein, penicillin-binding protein 1a, penicillin-binding protein 1B, penicillin-binding protein 2, penicillin-binding protein 3, peptidoglycan glycosyltransferase, peptidoglycan transglycosylase, PG-II, PGT, SgtB, SpoIID

ECTree

     2 Transferases
         2.4 Glycosyltransferases
             2.4.1 Hexosyltransferases
                2.4.1.129 peptidoglycan glycosyltransferase

Inhibitors

Inhibitors on EC 2.4.1.129 - peptidoglycan glycosyltransferase

Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
(2R)-2-[[(2S)-2-([[(2R,3R,4R,5S,6R)-5-[[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy]-4-[(1S)-1-carboxyethoxy]-2-[[(hexadecyloxy)(hydroxy)phosphoryl]oxy]-6-(hydroxymethyl)oxan-3-yl]carbamoyl]amino)propanoyl]amino]pentanedioic acid
-
-
(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R,3R,4R,5S,6R)-3-acetamido-2-([[(2R)-2-carboxy-2-(hexadecyloxy)ethoxy](hydroxy)phosphoryl]oxy)-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy]propanoyl]amino]propanoyl]amino]pentanedioic acid
-
-
(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R,3R,4R,5S,6R)-3-acetamido-2-[[(hexadecyloxy)(hydroxy)phosphoryl]oxy]-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy]propanoyl]amino]propanoyl]amino]pentanedioic acid
-
-
(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R,3S,4R,5R,6R)-3-[[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy]-5-(2-carboxyethyl)-6-([[(2R)-2-carboxy-2-(pentadecyloxy)ethoxy](hydroxy)phosphoryl]oxy)-2-(hydroxymethyl)oxan-4-yl]oxy]propanoyl]amino]propanoyl]amino]pentanedioic acid
-
-
(2R,3'R)-3-(3-O-(2-acetamido-2-deoxy-beta-D-glucopyranosyl)propylphosphinato)-2-(3',7'-dimethyloctyloxy)propanoic acid
-
0.1 mM, 25% inhibition, 0.2 mM, 37% inhibition
(2R,3'R)-3-[3-O-(2-acetamido-2-deoxy-beta-D-glucopyranosyl)propylphosphinato]-2-(3',7'-dimethyloctyloxy)propanoic acid
-
0.1 mM., 25% inhibition, 0.2 mM, 61% inhibition
(3E,7E,14E)-4,9,9,15,19-pentamethyl-12-methylideneicosa-3,7,14,18-tetraen-1-yl (2R)-3-[[[[(2R,3R,4S,5S,6S)-6-carbamoyl-3-[[(2S,3R,4R,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-([[3-(trifluoromethyl)phenyl]carbonyl]amino)tetrahydro-2H-pyran-2-yl]oxy]-5-hydroxy-4-([[4-(trifluoromethoxy)-3-(trifluoromethyl)phenyl]carbamoyl]amino)tetrahydro-2H-pyran-2-yl]oxy](hydroxy)phosphoryl]oxy]-2-hydroxypropanoate
(3Z)-5-(4-bromophenyl)-3-[(5-nitrofuran-2-yl)methylidene]furan-2(3H)-one
(4Z)-2,5-diphenyl-4-[2-(1,3-thiazol-2-yl)hydrazinylidene]-2,4-dihydro-3H-pyrazol-3-one
(E)-2-(1-(2-isobutoxyphenyl)-2-oxoindolin-3-ylidene)hydrazine-1-carboximidamide
-
(E)-2-(1-(4-(3-hydroxypropyl)phenyl)-2-oxoindolin-3-ylidene)hydrazine-1-carboximidamide
-
(E)-2-(1-(4-(ethoxymethyl)phenyl)-2-oxoindolin-3-ylidene)hydrazine-1-carboximidamide
-
(E)-2-(1-(4-(hydroxymethyl)phenyl)-2-oxoindolin-3-ylidene)hydrazine-1-carboximidamide
-
(E)-2-(1-(4-(methoxymethoxy)phenyl)-2-oxoindolin-3-ylidene)hydrazine-1-carboximidamide
-
(E)-2-(1-(4-(methoxymethyl)phenyl)-2-oxoindolin-3-ylidene)hydrazine-1-carboximidamide
-
(E)-2-(1-(4-(sec-butyl)phenyl)-2-oxoindolin-3-ylidene)hydrazine-1-carboximidamide
-
(E)-2-(1-(4-(tert-butoxymethyl)phenyl)-2-oxoindolin-3-ylidene)hydrazine-1-carboximidamide
-
(E)-2-(1-(4-butylphenyl)-2-oxoindolin-3-ylidene)hydrazine-1-carboximidamide
binding structure, modeling
(E)-2-(1-(4-ethoxyphenyl)-2-oxoindolin-3-ylidene)hydrazine-1-carboximidamide
-
(E)-2-(1-(4-ethylphenyl)-2-oxoindolin-3-ylidene)hydrazine-1-carboximidamide
-
(E)-2-(1-(4-hexylphenyl)-2-oxoindolin-3-ylidene)hydrazine-1-carboximidamide
-
(E)-2-(1-(4-hydroxyphenyl)-2-oxoindolin-3-ylidene)hydrazine-1-carboximidamide
-
(E)-2-(1-(4-octylphenyl)-2-oxoindolin-3-ylidene)hydrazine-1-carboximidamide
-
(E)-2-(1-(naphthalen-1-yl)-2-oxoindolin-3-ylidene)hydrazine-1-carboximidamide
-
(E)-2-(1-(naphthalen-2-yl)-2-oxoindolin-3-ylidene)hydrazine-1-carboximidamide
-
(E)-2-(3-(2-carbamimidoylhydrazineylidene)-2-oxoindolin-1-yl)-N-(3-(trifluoromethyl)phenyl)acetamide
-
(E)-2-(3-(2-carbamimidoylhydrazineylidene)-2-oxoindolin-1-yl)-N-(3-ethylphenyl)acetamide
-
(E)-2-(3-(2-carbamimidoylhydrazineylidene)-2-oxoindolin-1-yl)-N-(naphthalen-2-yl)acetamide
-
(E)-2-(3-(2-carbamimidoylhydrazineylidene)-5-methyl-2-oxoindolin-1-yl)-N-(3-nitrophenyl)acetamide
-
(R)-3-((2-acetamido-2-deoxy-beta-D-glucopyranosyl-(1-4)-alpha-D-glucopyranosyl)methylphosphinato)-2-octyloxypropanoic acid
-
0.1 mM, 17% inhibition
(R)-3-[3-O-(2-acetamido-2-deoxy-beta-D-glucopyranosyl-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranosyl)propylphosphinato]-2-octyloxypropanoic acid
-
0.1 mM, 10% inhibition
(Z)-2-(2-acetamido-2-deoxy-alpha-D-glucopyranosyl)oxymethyl-3-tetradecylbutenedioic acid dilithium salt
-
0.1 mM, 28% inhibition
(Z)-2-farnesyl-3-methylbutenedioic acid dilithium salt
-
weak inhibition
(Z)-2-geranyl-3-methylbutenedioic acid dilithium salt
-
0.1 mM, 12% inhibition
(Z)-2-nerolyl-3-methylbutenedioic acid dilithium salt
-
0.1 mM, 17% inhibition
2-(3-(2-carbamimidoylhydrazono)-2-oxoindolin-1-yl)-N-(3-nitrophenyl)acetamide
2-(3-(2-carbamimidoylhydrazono)-2-oxoindolin-1-yl)-N-(m-tolyl)acetamide
2-acetamido-3-O-[(1S)-1-carboxyethyl]-1-O-[[(2R)-2-carboxy-2-(hexadecyloxy)ethoxy](hydroxy)phosphoryl]-2-deoxy-alpha-D-glucopyranose
-
-
2-acetamido-4-O-(2-acetamido-2-deoxy-beta-D-glucopyranosyl)-3-O-[(1S)-1-carboxyethyl]-2-deoxy-1-O-[(hexadecyloxy)(hydroxy)phosphoryl]-alpha-D-glucopyranose
-
-
4-O-(2-acetamido-2-deoxy-beta-D-glucopyranosyl)-2-(carboxyamino)-3-O-[(1S)-1-carboxyethyl]-1-O-[[(2R)-2-carboxy-2-(pentadecyloxy)ethoxy](hydroxy)phosphoryl]-2-deoxy-alpha-D-glucopyranose
-
-
4-[(1E)-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)prop-1-en-1-yl]benzoic acid
4-[3-amino-3-([1,1'-biphenyl]-4-yl)propanamido]-1,5-anhydro-2,4-dideoxy-3-O-[2-deoxy-2-({[3-(trifluoromethyl)phenyl]carbamoyl}amino)-beta-D-glucopyranosyl]-2-({[3-(trifluoromethyl)phenyl]carbamoyl}amino)-D-galactitol
AC326-alpha
ACL19098
ACL19109
ACL19110
ACL19243
ACL19273
ACL19336
chaetomellic acid A dilithium salt
-
weak inhibition
chlorobiphenyl desleucyl vancomycin
chlorobiphenyl disaccharide
chlorobiphenyl vancomycin
Dimethylsulfoxide
-
in the presence of 0.05% N-lauroylsarcosine
enramycin
-
-
Garneau-5
macarbomycin
mersacidin
-
Moenomycin
moenomycin A
moenomycin disaccharide
moenomycin trisaccharide
neryl-moenomycin A
active site inhibitor
penicillin
Ristocetin
-
-
Sodium 1,2-cyclohexanediamine-N,N,N',N'-tetraacetic acid
-
in the absence of detergents, stimulates in the presence of high concentrations of methanol and detergents
sodium deoxycholate
-
in the presence of methanol, inhibits at 0.5%
Triton X-100
TS30153
tunicamycin
-
-
Vancomycin
additional information
-